Bioinformatic Analysis and Clinical Case Studies Identify CD276 as a Promising Diagnostic Biomarker for Clear Cell Renal Cell Carcinoma

Q: What is the main objective of this study regarding CD276 and ccRCC?

The study aims to assess the relationship between CD276 and clear cell renal carcinoma and evaluate CD276’s diagnostic value for ccRCC.

Q: How were CD276 expression levels measured in the study?

CD276 mRNA and protein levels were analyzed using immunohistochemistry and RT-PCR, comparing ccRCC tissues with para-cancer tissues; ELISA was used to assess peripheral blood samples.

Q: What did the diagnostic performance analysis show for CD276?

ROC curves generated from TCGA and GEO datasets indicated high diagnostic value for ccRCC, with AUC values reported as 0.894, 0.795, and 0.938.

Sep 21, 2026

Uploaded by Emma Wilson

Objective: Explore the relationship between CD276 and clear cell renal carcinoma (ccRCC) and evaluate CD276’s diagnostic value in ccRCC. Methods: Retrospective comparisons of CD276 expression in ccRCC versus para-cancer tissues used TCGA and GEO datasets, with prospective clinical data analysis; immunohistochemistry and RT-PCR measured mRNA/protein levels, ELISA tested peripheral blood, and ROC analysis with Kaplan–Meier generated diagnostic performance. Results: TCGA/GEO and clinical validation showed higher CD276 in ccRCC than paracancer tissues; ELISA distinguished ccRCC patients from healthy controls and showed higher peripheral CD276 with higher pathological grade.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages9

Reading Time23 min

AccessFree to download

Abstract

Introduction

Overview of ccRCC and clinical need

CD276 (B7-H3) background in cancer

Methods

Data sources (TCGA and GEO)

Tissue and blood assays (IHC, RT-PCR, ELISA)

Diagnostic performance evaluation (ROC)

Results

Expression differences in tissues

Peripheral blood findings and grade association

ROC/AUC performance

Conclusion

Bioinformatic Analysis and Clinical Case Studies Identify CD276 as a Promising Diagnostic Biomarker for Clear Cell Renal Cell Carcinoma Cancer Control Volume 31: 1–9 © The Author(s) 2024 Article reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions) [DOI: 10.1177/10732748241250181](DOI: 10.1177/10732748241250181)[ ](DOI: 10.1177/10732748241250181)[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx) Zhiyu Zhang, M. D. 1,* 􀀁, Jianhao Xu, M. D.2,*, Zhen Song, M. D.3,*, Jianglei Zhang, Ph. D. 1, Yuxin Lin, Ph. D.1, and Jun Ouyang, Ph. D. 1 Abstract Objective: This study aimed to explore the relationship between CD276 and clear cell renal carcinoma (ccRCC) and assess the diagnostic value of CD276 in ccRCC. Methods: Expression levels of CD276 in ccRCC and para-cancer tissues were compared and analyzed retrospectively using data obtained from TCGA and GEO databases. The clinical data was analyzed prospectively. Immunohistochemistry and RT-PCR analyses were used to analyze the expression of CD276 at the mRNA and protein levels. These analyses compared the expression between ccRCC tissues and para-cancer tissues obtained from 70 patients with ccRCC. Next, ELISA was used to analyze peripheral blood samples from 70 patients with ccRCC and 72 healthy individuals, facilitating the differentiation of ccRCC patients from normal controls. Finally, we utilized the Kaplan-Meier method to generate ROC curves for assessing the diagnostic value of CD276 for ccRCC. Results: Analysis of TCGA and GEO data revealed that the mRNA expression of CD276 was higher in ccRCC tissues than in paracancer tissues (P < .05). Clinical validation using IHC and RT-PCR conﬁrmed that the expression of CD276 was higher in ccRCC tissues than in para-cancer tissues, both at the mRNA and protein levels (P < .05). ELISA demonstrated that the expression of CD276 was higher in ccRCC patients than in normal individuals, and patients with a higher pathological grade showed higher expression of CD276 in the peripheral blood than those with a lower pathological grade (P < .05). ROC curves drawn from the above three datasets demonstrated that CD276 had a high diagnostic value for ccRCC (AUC = .894, .795, .938, respectively). Conclusion: The expression of CD276 was higher in ccRCC tissues and positively associated with the pathological grade. Therefore, CD276 may serve as a molecular biomarker for ccRCC prediction. Keywords CD276, biomarker, diagnosis, clear cell renal cell carcinoma Received December 2, 2023. Received revised March 5, 2024. Accepted for publication April 9, 2024. 1 Department of Urology, The First Afﬁliated Hospital of Soochow University, Suzhou, China 2Department of Pathology, The First People’s Hospital of Kunshan, Suzhou, China 3Department of Urology, Taixing People’s Hospital, Taizhou, China *These authors contributed equally to this work. Corresponding Author: Jun Ouyang, Department of Urology, The First Afﬁliated Hospital of Soochow University, No.188, Shizi Street, Gusu District, Suzhou 215006, China. Email: [dr_ouyangjun@126.com](dr_ouyangjun@126.com) Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as speciﬁed on the SAGE and Open Access pages ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/en-us/nam/open-access-at-sage)). Data Availability Statement included at the end of the article Introduction Renal cell carcinoma (RCC) originates from a malignant epithelial tumor of the renal tubules, accounting for 2-3% of all adult malignancies, and has the highest mortality rate among urological cancers.1

FAQs

What is the main objective of this study regarding CD276 and ccRCC?

The study aims to assess the relationship between CD276 and clear cell renal carcinoma and evaluate CD276’s diagnostic value for ccRCC.

How were CD276 expression levels measured in the study?

CD276 mRNA and protein levels were analyzed using immunohistochemistry and RT-PCR, comparing ccRCC tissues with para-cancer tissues; ELISA was used to assess peripheral blood samples.

What did the diagnostic performance analysis show for CD276?

ROC curves generated from TCGA and GEO datasets indicated high diagnostic value for ccRCC, with AUC values reported as 0.894, 0.795, and 0.938.

Sep 21, 2026

Uploaded by Emma Wilson